TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01725451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone
Description: Administered topically to axillae

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone
Description: Administered topically to axillae

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone
Description: Administered topically to axillae

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone
Description: Administered topically to axillae

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone
Description: Administered topically to axillae

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone
Description: Administered topically to axillae

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deodorant Spray
Description: Administered topically to axillae

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deodorant and Antiperspirant Combination Spray
Description: Administered topically to axillae

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deodorant and Antiperspirant Combination Spray
Description: Administered topically to axillae

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deodorant and Antiperspirant Combination Stick
Description: Administered topically to axillae
Study: NCT04428567

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dual-Task Treadmill exercise + Cognitive Training
Description: The dual-task regimen will include treadmill exercise of 5-10 min warm-up and cool-down, 30 minutes of running towards target heart rate, combined with respond demands with the addition of cognitive tasks. The level of duration and intensity of treadmill exercise will progressively increase over the duration of 6 weeks.
Study: NCT05665582

Intervention type: OTHER
Intervention: Family program
Description: A 4-day psychoeducational family program.
Study: NCT01648166

Intervention type: OTHER
Intervention: Environmental sampling
Description: Soil, water, blood, urine, hair and radon testing in homes in Appalachia

Intervention type: OTHER
Intervention: Environmental sampling
Description: Soil, water, blood, urine, hair and radon testing in homes in Appalachia
Study: NCT01002690

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoricoxib
Description: 90 mg/day orally for 10-13 days
Study: NCT02351726

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mitroflow DL
Description: Treatment with Mitroflow Pericardial Aortic Heart Valve with Phospholipid Reduction Therapy (Model DL)
Study: NCT00732290

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel then fluoxetine+clopidogrel
Description: D1 : clopidogrel (Plavix) 600mg (8 tablets) one time D45 to D48 : Fluoxetine (Fluoxetine EG 20mg) 20mg (1 tablet) per day D49 : 20mg Fluoxetine + 600mg Clopidogrel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoxetine+clopidogrel then clopidogrel
Description: D1 to D4 : Fluoxetine (Fluoxetine EG 20mg) 20mg (1 tablet) per day D5: 20mg Fluoxetine + Clopidogrel (Plavix) 600mg (8 tablets) one time D49 : Clopidogrel 600mg one time
Study: NCT03670238

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orogastric intubation
Description: Patient was placed in Fowler position (45º) and intraoral infiltrative anesthesia was carried out with Lidocaine 2% (without vasoconstrictor) at gingival papilla in the vestibular-palatine direction. A polyurethane enteral tube (Medicone®, Cachoeirinha - Brazil) was inserted through the mouth and passed into de stomach, followed by fixation of the tube tip to a superior molar or premolar, in its palatine surface. For dental amarry it waas used a suture wire in stainless steel size 1.0

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasogastric intubation
Description: After nostril anesthesia with xylocaine gel, a polyurethane enteral tube was inserted through the nose and its tip was positioned in the gastric lumen, according to the nose-ear-xiphoid method. The tube was attached to the face using antiallergic adhesive tape.
Study: NCT03988270

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Participant randomized to an exercise protocol using a hand grip device that is used on a daily basis. Participant will be encouraged to increase the number of repetitions used by the hand grip device during the course of the trial
Study: NCT03333226

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Axillary Reverse Mapping (ARM)
Description: ARM lymph node preservation versus removal

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Axillary Reverse Mapping (ARM)
Description: ARM lymph node preservation versus removal
Study: NCT02175797

Intervention type: DEVICE
Group type: OTHER
Intervention: MRI
Description: at least 6 weeks after the implantation of the pacemaker a MRI exam is performed
Study: NCT04260204

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pediatric cardiac surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pediatric cardiac surgery
Study: NCT01601678

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Peroral Endoscopic Myotomy (POEM)
Description: After lavage, measure gastro-esophageal junction (GEJ) in cm from mouth piece. Determine entry point 12-14cm above GEJ at the lesser curvature site, inject 10ml coloured saline, create entry point. Advance endoscope into the submucosa, dissect the submucosal tunnel up to 2-3cm into the cardia. Dissect the submucosa close to the muscularis and check endoluminally for the direction of the lesser curvature, sufficient extension onto the cardia and mucosal integrity. After tunnel completion flush with gentamycin and saline. Start myotomy from proximally to distally starting 4-5cm below the mucosal entry site; the inner circular muscle layer should be fully dissected especially at the cardia for good symptomatic results. It is vital that the mucosa of the tubular esophagus remains intact. Extend myotomy at least 2cm onto the cardia. After completion check for mucosal integrity and opening of the distal esophageal sphincter. Close the entry point with clips from distal to proximal.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Heller Myotomy (LHM)
Description: Use five trocar technique with patient in the French position as for laparoscopic anti-reflux procedures. Establish 12-15 mm Hg pneumoperitoneum. Use left paramedian trocar for camera, two lateral trocars for elevating liver and retraction of stomach and two trocars for dissection and suturing. Use of robotic surgery devices is allowed. Divide phrenoesophageal ligament starting on the right and mobilize distal esophagus on the lateral and anterior side. Identify and spare anterior vagal nerve. Perform myotomy by dividing both muscle-layers extending at least 6 cm above gastroesophageal junction and at least 2-3 cm inferiorly over stomach. Perform extent downwards after dividing epiphrenic fat pad overlying cardia. Measure myotomy length. Peroperative endoscopy check is advisable. Perform anterior fundoplication according to Dor. Only if necessary mobilize fundus of the stomach by dividing short gastric vessels. Suture fundus to both cut edges of myotomy, using non-resorbable material.
Study: NCT03946501

Intervention type: OTHER
Intervention: Data collection
Study: NCT00846625

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: triamcinolone
Description: Intravitreal injection (4 mg/0.1 ml)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab
Description: Intravitreal injection, 0.5 mg
Study: NCT01725425

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: The control is designed to determine average mood.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Increase Portion Size
Description: The purpose is to determine whether a change in mood will occur.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decrease Portion Size
Description: The purpose is to determine whether a change in mood will occur.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mixed Portions
Description: The purpose is to determine if a change in mood will occur.
Study: NCT04303338

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Masotherapy with neural tension and masotherapy with non-neural tension
Description: To compare the effectiveness of masotherapy with neural tension and masotherapy with non-neural tension

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Masotherapy with neural tension and masotherapy with non-neural tension
Description: To compare the effectiveness of masotherapy with neural tension and masotherapy with non-neural tension
Study: NCT00663221

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Anthocyans, Calcium and Vitamin D

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT01191320

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule 1x daily for 3 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androxal
Description: Capsules 12.5 mg or 25 mg 1x daily for 3 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androxal
Description: Capsules 12.5 mg or 25 mg 1x daily for 3 months
Study: NCT02627742

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MetaNeb® System
Description: The treatment protocol used for Respiratory Care during the CHANGE IN PRACTICE period of the Study will be that prescribed by the patient's health care team in the routine standard care of each patient. With the exception of standard airway clearance and lung expansion procedures, other components of the patients respiratory care regimen will remain the same as during the standard therapy period, however the CHANGE IN PRACTICE will incorporate the use/treatment with The MetaNeb® System as an alternative to usual airway clearance and lung expansion procedures. Use of The MetaNeb® System will follow the labeling of the device.
Study: NCT00689013

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized letter
Description: On Day 1 of the 2nd month, a personalized letter (addressing specific patient) was mailed to current pharmacy patients with indications for the Zostavax vaccine. Current patients were defined as those receiving at least one prescription medication from the pharmacy within 6 months. The personalized letter provided detailed information about herpes zoster infection, the vaccine for herpes zoster prevention, indications for vaccine receipt and contraindications for vaccine receipt.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flyer advertisement
Description: Beginning on Day 1 of the 2nd month, flyer advertisements were distributed with all pharmacy sales. Flyer advertisements provided detailed information about herpes zoster infection, the vaccine for herpes zoster prevention, indications for vaccine receipt and contraindications for vaccine receipt.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Newspaper press release
Description: During the first week of the 2nd month, local newspapers published press releases. The press release provided detailed information about herpes zoster infection, the vaccine for herpes zoster prevention, indications for vaccine receipt and contraindications for vaccine receipt.
Study: NCT04168346

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose
Description: Ferric carboxymaltose iv infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: NaCl 0.9% infusion
Study: NCT03160352

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exergame
Description: In total, 10 sessions were accomplished including baseline and post intervention measurements. The remaining eight exercise sessions lasted 40 minutes, with an actual training duration of 20 minutes. This resulted in a cumulative total intervention exercise time of 160 minutes.
Study: NCT02928913

Intervention type: OTHER
Intervention: No intervention

Intervention type: OTHER
Intervention: No intervention
Study: NCT03296475

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Abdominal Wall Closure Force (N).
Description: This measurement will be recorded for both the right and left anterior rectus sheath. We will measure this force at three anatomical points 1) at the level of the umbilicus and 2) at the halfway point between the pubic symphysis and the xiphisternum and 3) at the point of maximal hernia defect width.
Study: NCT04051970

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antiretroviral
Description: Antiretroviral treatments (ART) will be allocated through central randomization (1:1:) according to the following two strategies:~Tritherapy-Bitherapy (TRI-BI) strategy:~TRI between D0 and W16: 3-drug combination (3-DR) including 2 NRTI (either TDF or TAF+XTC) and a once daily integrase inhibitor (Stribild® or Genvoya® or Biktarvy®) or TDF/XTC Gé + Tivicay® or TDF/XTC Gé + Isentress® QD 1200 mg when available) during 16 weeks BI between W16 and W96: if pVL viral load \<500 cp/mL at W4 and \<50 cp/mL at W12, participants will start the 2-DR regimen TDF or TAF / XTC (TDF/XTC Gé or Descovy®) at W16, until W96.~(Descovy® : provided that it is available in France), (XTC = FTC or 3TC)~Immediate Bitherapy (BI) strategy Dolutegravir (DTG, Tivicay® 50 mg QD) plus lamivudine (3TC, 300 mg QD) between D0 and W96.~Antiretroviral drugs will be prescribed in the context of standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiretroviral
Description: Antiretroviral treatments (ART) will be allocated through central randomization (1:1:) according to the following two strategies:~Tritherapy-Bitherapy (TRI-BI) strategy:~TRI between D0 and W16: 3-drug combination (3-DR) including 2 NRTI (either TDF or TAF+XTC) and a once daily integrase inhibitor (Stribild® or Genvoya® or Biktarvy®) or TDF/XTC Gé + Tivicay® or TDF/XTC Gé + Isentress® QD 1200 mg when available) during 16 weeks BI between W16 and W96: if pVL viral load \<500 cp/mL at W4 and \<50 cp/mL at W12, participants will start the 2-DR regimen TDF or TAF / XTC (TDF/XTC Gé or Descovy®) at W16, until W96.~(Descovy® : provided that it is available in France), (XTC = FTC or 3TC)~Immediate Bitherapy (BI) strategy Dolutegravir (DTG, Tivicay® 50 mg QD) plus lamivudine (3TC, 300 mg QD) between D0 and W96.~Antiretroviral drugs will be prescribed in the context of standard of care.
Study: NCT02003183

Intervention type: RADIATION
Intervention: [F-18]FDDNP
Description: Each participant was injected with \[F-18\]FDDNP, a radiolabeled molecular imaging probe, prior to receiving a PET scan.
Study: NCT03256968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ataluren
Description: ataluren
Study: NCT03091946

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Overnight oats with additional dried fruits, nuts and seeds
Description: Oatmeal

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Cooked cream of rice with additional dried fruits, nuts and seeds
Description: Cooked cream of rice
Study: NCT04245826

Intervention type: OTHER
Intervention: Change in LCSBs Intake
Description: Effect of changing LCSBs intake

Intervention type: OTHER
Intervention: Substitute LCSBs for SSBs or Water
Description: Effect of substituting LCSBs for SSBs or Water
Study: NCT03535168

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1902607
Description: 3 different doses over the course of part 1 and 4 different doses over the course of part 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1902607
Description: 3 different doses over the course of part 1 and 4 different doses over the course of part 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1902607
Description: 3 different doses over the course of part 1 and 4 different doses over the course of part 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1902607
Description: 3 different doses over the course of part 1 and 4 different doses over the course of part 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1902607
Description: 3 different doses over the course of part 1 and 4 different doses over the course of part 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching placebo
Description: Matching placebo for BAY1902607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching placebo
Description: Matching placebo for BAY1902607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching placebo
Description: Matching placebo for BAY1902607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Part 1: The subjects will initially (Day -1) receive a sub-therapeutic dose of 1 mg midazolam as solution in the morning.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Part 1: The subjects will initially (Day -1) receive a sub-therapeutic dose of 1 mg midazolam as solution in the morning.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Part 1: The subjects will initially (Day -1) receive a sub-therapeutic dose of 1 mg midazolam as solution in the morning.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Part 1: The subjects will initially (Day -1) receive a sub-therapeutic dose of 1 mg midazolam as solution in the morning.
Study: NCT03508713

Intervention type: DRUG
Intervention: disease modified antirheumatic drugs or biological agents
Description: Enrolled patients will be treated according to the 2015 American College of Rheumatology Guideline for the Treatment of RA
Study: NCT03977051

Intervention type: BEHAVIORAL
Intervention: Focus group
Description: Kidneys transplant patients will discuss their attitudes and beliefs towards immunosuppressant medication adherence
Study: NCT03104738

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 25% reduction of basal insulin dose
Description: Subjects will be instructed to reduce their basal insulin dose to 75% instead of our institutional 50%.~Subject must check their own blood sugar before reporting to the hospital for their surgery. If the value is less than 70 or subjects are having symptoms of hypoglycemia, subjects will be instructed to immediately ingest 4-8 oz of fruit juice (without pulp) and call their doctor or the hospital.
Study: NCT00248638

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glutamine dipeptide with 15% Clinisol
Description: Subjects randomized to AG-PN will receive PN containing 0.5 g/kg/day of L alanyl L GLN (AG) dipeptide (Dipeptiven 20%; Fresenius-Kabi) and 1.0 g/kg/day of 15% Clinisol (Baxter Inc., Deerfield, IL) AA solution (total = 1.5 g/kg/day, with AG replacing 1/3 of Clinisol AA). The amount of GLN dipeptide administered each day will be determined by daily PN volume intake data.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 15% Clinisol
Description: Subjects randomized to STD-PN will receive 1.5 g/kg/day of 15% Clinisol. The amount of Clinisol administered each day will be determined by daily PN volume intake data.
Study: NCT01644500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dulaglutide
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dulaglutide
Description: Administered SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo as Capsules
Description: Placebo for glimepiride is administered orally as one to three capsules daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo as Capsules
Description: Placebo for glimepiride is administered orally as one to three capsules daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo as SC Injection
Description: Placebo for dulaglutide is administered as one SC injection.
Study: NCT00988923

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: group A: HYPERTHERMIA
Description: All patients were treated for 8 sessions, twice a week, for a total of 4 weeks of treatment. All patients were evaluated at baseline (T0) and after 4 weeks (T1). The first two sessions were sham-treatment for both groups

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: No intervention
Description: the intervention tool was switched in off, only bolus was activated
Study: NCT02467036

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Family Based Behavioral Treatment
Description: The intervention for both groups will be a 4-month Family-Based Behavioral Treatment (FBT), which includes dietary changes, physical activity changes, and behavioral therapy. Treatment is provided in separate parent and child groups. Families will learn to reduce caloric consumption and increase caloric expenditure (physical activity). Behavior therapy includes stimulus control, self-monitoring, goal setting and contracting, parenting skills, skills for managing high-risk situations, and maintenance and relapse prevention. Families will self-monitor caloric intake, breakfast consumption, physical activity, and hunger and satiety throughout the day.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Based Behavioral Treatment
Description: The intervention for both groups will be a 4-month Family-Based Behavioral Treatment (FBT), which includes dietary changes, physical activity changes, and behavioral therapy. Treatment is provided in separate parent and child groups. Families will learn to reduce caloric consumption and increase caloric expenditure (physical activity). Behavior therapy includes stimulus control, self-monitoring, goal setting and contracting, parenting skills, skills for managing high-risk situations, and maintenance and relapse prevention. Families will self-monitor caloric intake, breakfast consumption, physical activity, and hunger and satiety throughout the day.
Study: NCT01764438

Intervention type: PROCEDURE
Intervention: Primovist-enhanced MRI
Description: Performance of Primovist-enhanced MRI in HCC patients with very early or early stage disease, but with no suspicious intrahepatic HCC lesions by liver dynamic CT.
Study: NCT01599338

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: 3 months of treatment by Liraglutide (self-administration). The initial dose was 0.6 mg/day subcutaneously during five days, then uptitrated to a daily dose of 1.2 mg during three months.
Study: NCT03488342

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Repair for primary inguinal hernia
Description: Repair for primary inguinal hernia

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Repair for primary inguinal hernia
Description: Repair for primary inguinal hernia
Study: NCT02947009

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diagnostic Study
Description: Participants will undergo laryngoscopy at baseline and with exercise challenge and will rate severity of various symptoms related to the larynx (ex. shortness of breath, voice changes, cough).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diagnostic Study
Description: Participants will undergo laryngoscopy at baseline and with exercise challenge and will rate severity of various symptoms related to the larynx (ex. shortness of breath, voice changes, cough).